Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA In Twilight: Gov’t Shutdown Has Not Slowed Rx Operations Too Visibly Yet

Executive Summary

Shutdown puts API shipments on a slow boat, but reviews of existing products can proceed with carry-over funds, even as new applications cannot be filed. CDC has largely halted its influenza program and NIH has ceased enrolling new patients in its clinical center.


Related Content

US FDA Enters Shutdown Mode: Reviews Will Continue, But Will Morale?
FDA's Government Shutdown Plan Ready, Just In Case
FDA Shutdown Hangover Hurts Biosimilars, May Benefit Some ANDAs
FDA in the Shutdown: Drug Center Stays Open (Mostly); Ben Venue Does Not
Shutdown Week Two: Could Sponsors Find A More Focused FDA?
Baxter’s Clinolipid Could Offer Safety Advantages While Mitigating Shortage
Merck’s Allergy Immunotherapy Suffers Review Delay Under Gov’t Shutdown
Shutdown Realities At FDA: No New Submission Reviews, And More
PhRMA Seeking Injunction Against 340B Orphan Drug Exclusion Rule
FDA’s Shutdown Plan: Some User Fee Services Would Continue; Routine Inspections Would Not


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts